Skip to main content
← Companies
CPRX

CATALYST PHARMACEUTICALS, INC.

Data as of Sep 17, 2026
CPRX
CIK 1369568Pharmaceutical Preparations

Lobbying

$270,000 in reported federal lobbying spend across 9 quarterly filings, most recently Jul 20, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.

Spend by issue

  • Health Issues$270K9 filings

Latest filings, Sep 2025 onward

FiledRegistrant and subjectAmount
Jul 20, 2026
JEFFREY J. KIMBELL & ASSOCIATES, INC. for CATALYST PHARMACEUTICALS
Health Issues General FDA issues related to orphan drugs
$30,000
Apr 20, 2026
JEFFREY J. KIMBELL & ASSOCIATES, INC. for CATALYST PHARMACEUTICALS
Health Issues General FDA issues related to orphan drugs
$30,000
Mar 9, 2026
JEFFREY J. KIMBELL & ASSOCIATES, INC. for CATALYST PHARMACEUTICALS
Health Issues General FDA issues related to orphan drugs
$30,000
Jan 20, 2026
JEFFREY J. KIMBELL & ASSOCIATES, INC. for CATALYST PHARMACEUTICALS
Health Issues General FDA issues related to orphan drugs
$30,000
Oct 20, 2025
JEFFREY J. KIMBELL AND ASSOCIATES for CATALYST PHARMACEUTICALS
Health Issues General FDA issues related to orphan drugs
$30,000
Sep 25, 2025
JEFFREY J. KIMBELL & ASSOCIATES, INC. for CATALYST PHARMACEUTICALS
Health Issues General FDA issues related to orphan drugs
$30,000

Data: Quiver Quantitative, FEC, Senate Lobbying Disclosure Act filings, USAspending, congressional periodic transaction reports. Records are matched to CATALYST PHARMACEUTICALS, INC. through its SEC registration (CIK 1369568) and tickers CPRX.

As of: lobbying filings through Jul 20, 2026; contract actions through Jul 18, 2026. Snapshot rebuilt Sep 17, 2026.

Holdings values are estimates from disclosed ranges. Donation coverage for a cycle begins with the first month loaded, so earlier months may still be missing.